Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 May 16;25(20):4085-92.
doi: 10.1016/j.vaccine.2007.02.050. Epub 2007 Mar 7.

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine

Andrew T Catanzaro  1 , Mario Roederer, Richard A Koup, Robert T Bailer, Mary E Enama, Martha C Nason, Julie E Martin, Steve Rucker, Charla A Andrews, Phillip L Gomez, John R Mascola, Gary J Nabel, Barney S Graham; VRC 007 Study Team
Affiliations
Clinical Trial

Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine

Andrew T Catanzaro et al. Vaccine. .

Abstract

Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4(+) [13/14 (93%)] and CD8(+) [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation.

PubMed Disclaimer

Publication types

MeSH terms